Investing.com -- Johnson & Johnson (NYSE:JNJ) has reported second-quarter adjusted earnings per share of $2.80 on sales of $25.53 billion, both of which beat Bloomberg consensus estimates.
The pharmaceutical giant also improved its 2023 profit forecast.